Partial recovery of peripheral blood monocyte subsets in head and neck squamous cell carcinoma patients upon radio(chemo)therapy is associated with decreased plasma CXCL11.
Adhesion molecules
CXCL11
Head and Neck squamous cell carcinoma
Monocyte subsets
PD-L1
Radio(chemo)therapy
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
12 Apr 2024
12 Apr 2024
Historique:
received:
24
01
2024
accepted:
24
03
2024
medline:
13
4
2024
pubmed:
13
4
2024
entrez:
12
4
2024
Statut:
epublish
Résumé
Head and neck squamous cell carcinoma (HNSCC) represents a common and heterogeneous malignancy of the oral cavity, pharynx and larynx. Surgery and radio(chemo)therapy are the standard treatment options and also have great influence on the composition of the tumor microenvironment and immune cell functions. However, the impact of radio(chemo)therapy on the distribution and characteristics of circulating monocyte subsets in HNSCC are not fully understood. Expression patterns of adhesion molecules and chemokine receptors CD11a (integrin-α L; LFA-1), CD11b (integrin-α M; Mac-1), CD11c (integrin-α X), CX3CR1 (CX3CL1 receptor) and checkpoint molecule PD-L1 (programmed cell death ligand-1) were investigated upon radio(chemo)therapeutic treatment using flow cytometry. Furthermore, comprehensive analysis of plasma cytokines was performed before and after treatment using ELISA measurements. Our data reveal a partial recovery of circulating monocytes in HNSCC patients upon radio(chemo)therapeutic treatment, with differential effects of the individual therapy regimen. PD-L1 expression on non-classical monocytes significantly correlates with the individual plasma levels of chemokine CXCL11 (C-X-C motif chemokine 11). Further comprehensive investigations on larger patient cohorts are required to elucidate the meaningfulness of peripheral blood monocyte subsets and chemokine CXCL11 as potential bioliquid indicators in HNSCC with regard to therapy response and the individual immunological situation.
Sections du résumé
BACKGROUND
BACKGROUND
Head and neck squamous cell carcinoma (HNSCC) represents a common and heterogeneous malignancy of the oral cavity, pharynx and larynx. Surgery and radio(chemo)therapy are the standard treatment options and also have great influence on the composition of the tumor microenvironment and immune cell functions. However, the impact of radio(chemo)therapy on the distribution and characteristics of circulating monocyte subsets in HNSCC are not fully understood.
METHODS
METHODS
Expression patterns of adhesion molecules and chemokine receptors CD11a (integrin-α L; LFA-1), CD11b (integrin-α M; Mac-1), CD11c (integrin-α X), CX3CR1 (CX3CL1 receptor) and checkpoint molecule PD-L1 (programmed cell death ligand-1) were investigated upon radio(chemo)therapeutic treatment using flow cytometry. Furthermore, comprehensive analysis of plasma cytokines was performed before and after treatment using ELISA measurements.
RESULTS
RESULTS
Our data reveal a partial recovery of circulating monocytes in HNSCC patients upon radio(chemo)therapeutic treatment, with differential effects of the individual therapy regimen. PD-L1 expression on non-classical monocytes significantly correlates with the individual plasma levels of chemokine CXCL11 (C-X-C motif chemokine 11).
CONCLUSIONS
CONCLUSIONS
Further comprehensive investigations on larger patient cohorts are required to elucidate the meaningfulness of peripheral blood monocyte subsets and chemokine CXCL11 as potential bioliquid indicators in HNSCC with regard to therapy response and the individual immunological situation.
Identifiants
pubmed: 38609887
doi: 10.1186/s12885-024-12177-x
pii: 10.1186/s12885-024-12177-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
459Informations de copyright
© 2024. The Author(s).
Références
Pfister DG, Spencer S, Adelstein D, Adkins D, Anzai Y, Brizel DM, et al. Head and neck cancers, version 2.2020, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Cancer Netw. 2020;18(7):873–98.
doi: 10.6004/jnccn.2020.0031
Zhang P, Li S, Zhang T, Cui F, Shi JH, Zhao F, et al. Characterization of molecular subtypes in head and neck squamous cell carcinoma with distinct prognosis and treatment responsiveness. Front Cell Dev Biology. 2021;9:711348.
doi: 10.3389/fcell.2021.711348
De Felice F, Cattaneo CG, Franco P. Radiotherapy and systemic therapies: focus on head and neck Cancer. Cancers. 2023;15(17):4232.
pubmed: 37686508
pmcid: 10486947
doi: 10.3390/cancers15174232
Lacas B, Carmel A, Landais C, Wong SJ, Licitra L, Tobias JS, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiotherapy Oncology: J Eur Soc Therapeutic Radiol Oncol. 2021;156:281–93.
doi: 10.1016/j.radonc.2021.01.013
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64.
pubmed: 22437870
pmcid: 4856023
doi: 10.1038/nrc3239
An Q, Liu Z. Comparative efficacy and safety of combination therapies for advanced melanoma: a network meta-analysis. BMC Cancer. 2019;19(1):43.
pubmed: 30626368
pmcid: 6327485
doi: 10.1186/s12885-018-5259-8
Ichiki Y, Taira A, Chikaishi Y, Matsumiya H, Mori M, Kanayama M, et al. Prognostic factors of advanced or postoperative recurrent non-small cell lung cancer targeted with immune check point inhibitors. J Thorac Disease. 2019;11(4):1117–23.
doi: 10.21037/jtd.2019.04.41
Ruckert M, Flohr AS, Hecht M, Gaipl US. Radiotherapy and the immune system: more than just immune suppression. Stem Cells. 2021;39(9):1155–65.
pubmed: 33961721
doi: 10.1002/stem.3391
Bauer M, Goldstein M, Christmann M, Becker H, Heylmann D, Kaina B. Human monocytes are severely impaired in base and DNA double-strand break repair that renders them vulnerable to oxidative stress. Proc Natl Acad Sci USA. 2011;108(52):21105–10.
pubmed: 22160723
pmcid: 3248544
doi: 10.1073/pnas.1111919109
Wunderlich R, Ernst A, Rodel F, Fietkau R, Ott O, Lauber K, et al. Low and moderate doses of ionizing radiation up to 2 Gy modulate transmigration and chemotaxis of activated macrophages, provoke an anti-inflammatory cytokine milieu, but do not impact upon viability and phagocytic function. Clin Exp Immunol. 2015;179(1):50–61.
pubmed: 24730395
doi: 10.1111/cei.12344
Hart L, Ogbonnaya A, Boykin K, Deyoung K, Bailey R, Heritage T, et al. Burden of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer: a retrospective study from community oncology practices. Cancer Med. 2023;12(8):10020–30.
pubmed: 37000119
pmcid: 10166910
doi: 10.1002/cam4.5738
Brandmaier A, Formenti SC. The impact of radiation therapy on innate and adaptive tumor immunity. Semin Radiat Oncol. 2020;30(2):139–44.
pubmed: 32381293
doi: 10.1016/j.semradonc.2019.12.005
Li B, Ren M, Zhou X, Han Q, Cheng L. Targeting tumor-associated macrophages in head and neck squamous cell carcinoma. Oral Oncol. 2020;106: 104723.
pubmed: 32315971
doi: 10.1016/j.oraloncology.2020.104723
Wagner F, Holig U, Wilczkowski F, Plesca I, Sommer U, Wehner R, et al. Neoadjuvant radiochemotherapy significantly alters the phenotype of plasmacytoid dendritic cells and 6-Sulfo LacNAc(+) monocytes in rectal cancer. Front Immunol. 2019;10:602.
pubmed: 30984181
pmcid: 6450462
doi: 10.3389/fimmu.2019.00602
Tojo M, Horie H, Koinuma K, Miyato H, Tsukui H, Kaneko Y, et al. Programmed cell death ligand 1 expression on monocytes is inversely correlated with tumour response to preoperative chemoradiotherapy for locally advanced rectal cancer. Colorectal Dis. 2022;24(10):1140–9.
doi: 10.1111/codi.16167
Stefater JA 3, Ren S, Lang RA, Duffield JS. Metchnikoff’s policemen: macrophages in development, homeostasis and regeneration. Trends Mol Med. 2011;17(12):743–52.
pubmed: 21890411
pmcid: 3225647
doi: 10.1016/j.molmed.2011.07.009
Wong KL, Yeap WH, Tai JJ, Ong SM, Dang TM, Wong SC. The three human monocyte subsets: implications for health and disease. Immunol Res. 2012;53(1–3):41–57.
pubmed: 22430559
doi: 10.1007/s12026-012-8297-3
Ziegler-Heitbrock L. Blood monocytes and their subsets: established features and open questions. Front Immunol. 2015;6: 423.
pubmed: 26347746
pmcid: 4538304
doi: 10.3389/fimmu.2015.00423
Patel AA, Zhang Y, Fullerton JN, Boelen L, Rongvaux A, Maini AA, et al. The fate and lifespan of human monocyte subsets in steady state and systemic inflammation. J Exp Med. 2017;214(7):1913–23.
pubmed: 28606987
pmcid: 5502436
doi: 10.1084/jem.20170355
Boyette LB, Macedo C, Hadi K, Elinoff BD, Walters JT, Ramaswami B, et al. Phenotype, function, and differentiation potential of human monocyte subsets. PLoS ONE. 2017;12(4): e0176460.
pubmed: 28445506
pmcid: 5406034
doi: 10.1371/journal.pone.0176460
Idel C, Loyal K, Rades D, Hakim SG, Schumacher U, Bruchhage KL, et al. Smoking-, alcohol-, and age-related alterations of blood monocyte subsets and circulating CD4/CD8 T cells in head and neck cancer. Biology. 2022;11(5):658.
pubmed: 35625386
pmcid: 9138171
doi: 10.3390/biology11050658
Weber C, Belge KU, von Hundelshausen P, Draude G, Steppich B, Mack M, et al. Differential chemokine receptor expression and function in human monocyte subpopulations. J Leukoc Biol. 2000;67(5):699–704.
pubmed: 10811011
doi: 10.1002/jlb.67.5.699
Polasky C, Steffen A, Loyal K, Lange C, Bruchhage KL, Pries R. Redistribution of monocyte subsets in obstructive sleep apnea syndrome patients leads to an imbalanced PD-1/PD-L1 cross-talk with CD4/CD8 T cells. J Immunol. 2021;206(1):51–8.
pubmed: 33268482
doi: 10.4049/jimmunol.2001047
Kumaravel S, Singh S, Roy S, Venkatasamy L, White TK, Sinha S, et al. CXCL11-CXCR3 axis mediates tumor lymphatic cross talk and inflammation-induced tumor, promoting pathways in head and neck cancers. Am J Pathol. 2020;190(4):900–15.
pubmed: 32035061
pmcid: 7180517
doi: 10.1016/j.ajpath.2019.12.004
Wang X, Zhang J, Zhou G. The CXCL11-CXCR3A axis influences the infiltration of CD274 and IDO1 in oral squamous cell carcinoma. J oral Pathol Medicine: Official Publication Int Association Oral Pathologists Am Acad Oral Pathol. 2021;50(4):362–70.
doi: 10.1111/jop.13130
Atun R, Jaffray DA, Barton MB, Bray F, Baumann M, Vikram B, et al. Expanding global access to radiotherapy. Lancet Oncol. 2015;16(10):1153–86.
pubmed: 26419354
doi: 10.1016/S1470-2045(15)00222-3
Citrin DE. Recent developments in radiotherapy. N Engl J Med. 2017;377(22):2200–1.
pubmed: 29171815
doi: 10.1056/NEJMc1713349
Jarosz-Biej M, Smolarczyk R, Cichon T, Kulach N. Tumor microenvironment as a game changer in cancer radiotherapy. Int J Mol Sci. 2019;20(13):3212.
pubmed: 31261963
pmcid: 6650939
doi: 10.3390/ijms20133212
Moriyama Y, Horita N, Kudo M, Shinkai M, Fujita H, Yamanaka T, et al. Monocyte nadir is a possible indicator for neutrophil nadir during lung cancer chemotherapy. Clin Respir J. 2017;11(4):453–8.
pubmed: 26260239
doi: 10.1111/crj.12358
Ouyang W, Liu Y, Deng D, Zhou F, Xie C. The change in peripheral blood monocyte count: a predictor to make the management of chemotherapy-induced neutropenia. J Cancer Res Ther. 2018;14(Supplement):S565-570.
pubmed: 30249869
Soeda A, Morita-Hoshi Y, Makiyama H, Morizane C, Ueno H, Ikeda M, et al. Regular dose of gemcitabine induces an increase in CD14 + monocytes and CD11c + dendritic cells in patients with advanced pancreatic cancer. Jpn J Clin Oncol. 2009;39(12):797–806.
pubmed: 19797418
doi: 10.1093/jjco/hyp112
Valdes-Ferrada J, Munoz-Durango N, Perez-Sepulveda A, Muniz S, Coronado-Arrazola I, Acevedo F, et al. Peripheral blood classical monocytes and plasma interleukin 10 are Associated to neoadjuvant chemotherapy response in breast cancer patients. Front Immunol. 2020;11: 1413.
pubmed: 32733470
pmcid: 7363840
doi: 10.3389/fimmu.2020.01413
Cassetta L, Fragkogianni S, Sims AH, Swierczak A, Forrester LM, Zhang H, et al. Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets. Cancer Cell. 2019;35(4):588-e60210.
pubmed: 30930117
pmcid: 6472943
doi: 10.1016/j.ccell.2019.02.009
Kiss M, Caro AA, Raes G, Laoui D. Systemic reprogramming of monocytes in cancer. Front Oncol. 2020;10: 1399.
pubmed: 33042791
pmcid: 7528630
doi: 10.3389/fonc.2020.01399
Coffelt SB, Kersten K, Doornebal CW, Weiden J, Vrijland K, Hau CS, et al. IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis. Nature. 2015;522(7556):345–8.
pubmed: 25822788
pmcid: 4475637
doi: 10.1038/nature14282
Galluzzi L, Humeau J, Buque A, Zitvogel L, Kroemer G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Reviews Clin Oncol. 2020;17(12):725–41.
doi: 10.1038/s41571-020-0413-z
Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity. 2013;39(1):74–88.
pubmed: 23890065
doi: 10.1016/j.immuni.2013.06.014
Heylmann D, Ponath V, Kindler T, Kaina B. Comparison of DNA repair and radiosensitivity of different blood cell populations. Sci Rep. 2021;11(1):2478.
pubmed: 33510180
pmcid: 7843614
doi: 10.1038/s41598-021-81058-1
Ingalls RR, Golenbock DT. CD11c/CD18, a transmembrane signaling receptor for lipopolysaccharide. J Exp Med. 1995;181(4):1473–9.
pubmed: 7535339
doi: 10.1084/jem.181.4.1473
Postigo AA, Corbi AL, Sanchez-Madrid F, de Landazuri MO. Regulated expression and function of CD11c/CD18 integrin on human B lymphocytes. Relation between attachment to fibrinogen and triggering of proliferation through CD11c/CD18. J Exp Med. 1991;174(6):1313–22.
pubmed: 1683891
doi: 10.1084/jem.174.6.1313
Dupuy AG, Caron E. Integrin-dependent phagocytosis - spreading from microadhesion to new concepts. J Cell Sci. 2008;121(11):1773–83.
pubmed: 18492791
doi: 10.1242/jcs.018036
McDermott DH, Halcox JPJ, Schenke WH, Waclawiw MA, Merrell MN, Epstein N, et al. Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ Res. 2001;89(5):401–7.
pubmed: 11532900
doi: 10.1161/hh1701.095642
Tacke F, Alvarez D, Kaplan TJ, Jakubzick C, Spanbroek R, Llodra J, et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest. 2007;117(1):185–94.
pubmed: 17200718
pmcid: 1716202
doi: 10.1172/JCI28549
Auffray C, Fogg D, Garfa M, Elain G, Join-Lambert O, Kayal S, et al. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science. 2007;317(5838):666–70.
pubmed: 17673663
doi: 10.1126/science.1142883
Jenei V, Burai S, Molnar T, Kardos B, Macsik R, Toth M, et al. Comparison of the immunomodulatory potential of platinum-based anti-cancer drugs and anthracyclins on human monocyte-derived cells. Cancer Chemother Pharmacol. 2023;91(1):53–66.
pubmed: 36451019
doi: 10.1007/s00280-022-04497-1
Kalbasi A, Komar C, Tooker GM, Liu M, Lee JW, Gladney WL, et al. Tumor-derived CCL2 mediates resistance to radiotherapy in pancreatic ductal adenocarcinoma. Clin Cancer Res. 2017;23(1):137–48.
doi: 10.1158/1078-0432.CCR-16-0870
Mondini M, Loyher PL, Hamon P, Gerbe de Thore M, Laviron M, Berthelot K, et al. CCR2-dependent recruitment of tregs and monocytes following radiotherapy is associated with TNFalpha-mediated resistance. Cancer Immunol Res. 2019;7(3):376–87.
pubmed: 30696630
doi: 10.1158/2326-6066.CIR-18-0633
Shin SC, Lee KM, Kang YM, Kim K, Kim CS, Yang KH, et al. Alteration of cytokine profiles in mice exposed to chronic low-dose ionizing radiation. Biochem Biophys Res Commun. 2010;397(4):644–9.
pubmed: 20513358
doi: 10.1016/j.bbrc.2010.05.121
Ye X, Liu J, Quan R, Lu Y, Zhang J. DKK1 affects survival of patients with head and neck squamous cell carcinoma by inducing resistance to radiotherapy and immunotherapy. Radiotherapy Oncology: J Eur Soc Therapeutic Radiol Oncol. 2023;181:109485.
doi: 10.1016/j.radonc.2023.109485
Plattel WJ, Alsada ZN, van Imhoff GW, Diepstra A, van den Berg A, Visser L. Biomarkers for evaluation of treatment response in classical Hodgkin lymphoma: comparison of sGalectin-1, sCD163 and sCD30 with TARC. Br J Haematol. 2016;175(5):868–75.
pubmed: 27610595
doi: 10.1111/bjh.14317
Aderhold C, Umbreit C, Faber A, Sauter A, Sommer JU, Birk R, et al. Chemotherapeutic alteration of VEGF, PDGF and PDGFRalpha/beta expression under 5-FU vs. docetaxel in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro. Anticancer Res. 2013;33(5):1951–61.
pubmed: 23645743
Lin LH, Lin JS, Yang CC, Cheng HW, Chang KW, Liu CJ. Overexpression of platelet-derived growth factor and its receptor are correlated with oral tumorigenesis and poor prognosis in oral squamous cell carcinoma. Int J Mol Sci. 2020;21(7):2360.
pubmed: 32235327
pmcid: 7177415
doi: 10.3390/ijms21072360
Graves DT, Grotendorst GR, Antoniades HN, Schwartz CJ, Valente AJ. Platelet-derived growth factor is not chemotactic for human peripheral blood monocytes. Exp Cell Res. 1989;180(2):497–503.
pubmed: 2914581
doi: 10.1016/0014-4827(89)90076-1
Gao YJ, Liu L, Li S, Yuan GF, Li L, Zhu HY, et al. Down-regulation of CXCL11 inhibits colorectal cancer cell growth and epithelial-mesenchymal transition. OncoTargets Therapy. 2018;11:7333–43.
pubmed: 30425523
pmcid: 6205823
doi: 10.2147/OTT.S167872
Hwang HJ, Lee YR, Kang D, Lee HC, Seo HR, Ryu JK, et al. Endothelial cells under therapy-induced senescence secrete CXCL11, which increases aggressiveness of breast cancer cells. Cancer Lett. 2020;490:100–10.
pubmed: 32659248
doi: 10.1016/j.canlet.2020.06.019
Wang G, Zhang Z, Zhong K, Wang Z, Yang N, Tang X, et al. CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma. Mol Therapy. 2023;31(1):134–53.
doi: 10.1016/j.ymthe.2022.08.021
Zhai D, An D, Wan C, Yang K. Radiotherapy: brightness and darkness in the era of immunotherapy. Transl Oncol. 2022;19:101366.
pubmed: 35219093
pmcid: 8881489
doi: 10.1016/j.tranon.2022.101366
Radmanic L, Simicic P, Bodulic K, Vince A, Zidovec-Lepej S. Antiviral treatment significantly reduces the levels of CXCL9, CXCL10 and CXCL11 in chronic hepatitis C. Cytokine. 2024;176:156529.
pubmed: 38335772
doi: 10.1016/j.cyto.2024.156529
Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027–34.
pubmed: 11015443
pmcid: 2193311
doi: 10.1084/jem.192.7.1027
Probst HC, McCoy K, Okazaki T, Honjo T, van den Broek M. Resting dendritic cells induce peripheral CD8 + T cell tolerance through PD-1 and CTLA-4. Nat Immunol. 2005;6(3):280–6.
pubmed: 15685176
doi: 10.1038/ni1165
Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med. 2006;203(4):883–95.
pubmed: 16606670
pmcid: 2118286
doi: 10.1084/jem.20051776
Tsushima F, Yao S, Shin T, Flies A, Flies S, Xu H, et al. Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. Blood. 2007;110(1):180–5.
pubmed: 17289811
pmcid: 1896111
doi: 10.1182/blood-2006-11-060087
Dave K, Ali A, Magalhaes M. Increased expression of PD-1 and PD-L1 in oral lesions progressing to oral squamous cell carcinoma: a pilot study. Sci Rep. 2020;10(1):9705.
pubmed: 32546692
pmcid: 7297711
doi: 10.1038/s41598-020-66257-6
Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11(11):3887–95.
pubmed: 1396582
pmcid: 556898
doi: 10.1002/j.1460-2075.1992.tb05481.x
Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018;18(3):153–67.
pubmed: 28990585
doi: 10.1038/nri.2017.108
Thibult ML, Mamessier E, Gertner-Dardenne J, Pastor S, Just-Landi S, Xerri L, et al. PD-1 is a novel regulator of human B-cell activation. Int Immunol. 2013;25(2):129–37.
pubmed: 23087177
doi: 10.1093/intimm/dxs098
Kuang DM, Peng C, Zhao Q, Wu Y, Chen MS, Zheng L. Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells. Hepatology. 2010;51(1):154–64.
pubmed: 19902483
doi: 10.1002/hep.23291
Heeren AM, Punt S, Bleeker MC, Gaarenstroom KN, van der Velden J, Kenter GG, et al. Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix. Mod Pathol. 2016;29(7):753–63.
doi: 10.1038/modpathol.2016.64
Kim HR, Ha SJ, Hong MH, Heo SJ, Koh YW, Choi EC, et al. PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients. Sci Rep. 2016;6: 36956.
pubmed: 27841362
pmcid: 5107906
doi: 10.1038/srep36956
Shinchi Y, Ishizuka S, Komohara Y, Matsubara E, Mito R, Pan C, et al. The expression of PD-1 ligand 1 on macrophages and its clinical impacts and mechanisms in lung adenocarcinoma. Cancer Immunol Immunotherapy: CII. 2022;71(11):2645–61.
pubmed: 35352168
doi: 10.1007/s00262-022-03187-4
Kzhyshkowska J, Gudima A, Moganti K, Gratchev A, Orekhov A. Perspectives for monocyte/macrophage-based diagnostics of chronic inflammation. Transfus Med Hemother. 2016;43(2):66–77.
doi: 10.1159/000444943
Wang NH, Lei Z, Yang HN, Tang Z, Yang MQ, Wang Y, et al. Radiation-induced PD-L1 expression in tumor and its microenvironment facilitates cancer-immune escape: a narrative review. Annals Translational Med. 2022;10(24):1406.
doi: 10.21037/atm-22-6049